Zingg et al. (2018) showed that EZH2 is a melanoma driver by deconstructing the primary cilia through silencing of cilia genes. They showed that gain of EZH2 promotes loss of primary cilia in benign melanocytic lesions (Zingg et al., 2018). In contrast, blockade of EZH2 activity evokes ciliogenesis and cilia-dependent growth inhibition in malignant melanoma (Zingg et al., 2018). The gene discussed is EZH2; the disease is melanoma.